Primmune Therapeutics, Inc.
2:45 PM - 3:00 PM (EST), Tuesday, February 7, 2023 ・ Palace
Primmune Therapeutics is developing PRTX007 as a systemic oral innate immune therapy for solid tumors (adjuvant/combo w/CPIs) and as single agent therapy for clearance of HPV driven cervical pre-cancerous lesions and infections.
We recently completed a large healthy volunteer phase I SAD/MAD study (n = 130) with PRTX007 dosed orally on a continuous basis.
PRTX007's safety, tolerability, PK and innate/adaptive immune PD data were as we predicted based on our extensive PO in vivo primate and in vitro hPBMC studies.
PRTX007 is a novel oral systemically acting TLR7 agonist that drives a very well tolerated AUC dependent poly-IFN response (via IRF7) with no meaningful NFKB pro-inflammatory cytokines activity.
In addition to stimulating clinically meaningful ISG and chemokine/cytokine responses; PRTX007 also drove meaningful systemic T and NK cell activation/proliferation. In murine tumor models, PRTX007 also demonstrated synergistic T-Cell increases in the TME w/ CPIs
We recently completed a large healthy volunteer phase I SAD/MAD study (n = 130) with PRTX007 dosed orally on a continuous basis.
PRTX007's safety, tolerability, PK and innate/adaptive immune PD data were as we predicted based on our extensive PO in vivo primate and in vitro hPBMC studies.
PRTX007 is a novel oral systemically acting TLR7 agonist that drives a very well tolerated AUC dependent poly-IFN response (via IRF7) with no meaningful NFKB pro-inflammatory cytokines activity.
In addition to stimulating clinically meaningful ISG and chemokine/cytokine responses; PRTX007 also drove meaningful systemic T and NK cell activation/proliferation. In murine tumor models, PRTX007 also demonstrated synergistic T-Cell increases in the TME w/ CPIs
Company Type:
Privately Funded Company
Company Website:
Company HQ State:
California
Company HQ Country:
United States
Year Founded:
2017
Main Therapeutic Focus:
Oncology
Lead Product in Development:
PRTX007
Development Phase of Primary Product:
Phase II
Number Of Unlicensed Products (For Which You Are Seeking Partners):
1
Speaker
